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Quasispecies of infectious bursal disease virus (IBDV) vaccine and wild-type strains were identified using real-time RT-PCR
at a region of the viral genome known for sequence variability. The LightCycler (Idaho Technology, Inc.) and hybridization
probe system (Roche, Molecular Biochemicals) were used. An anchor probe labeled with LightCycler Red 640 and mutation
probe labeled with fluorescein were designed using the Del-E IBDV sequence. The sequence of the mutation probe included
nucleotides in the hydrophilic B region of VP2 that are important to a viral neutralizing epitope. This Del-E mutation probe was
allowed to hybridize to the RT-PCR products following amplification and its temperature of dissociation (Tm) from each viral
template was determined using the LightCycler melting peak analysis. The observed Tm for the Del-E mutation probe with its
homologous virus, Del-E, was usually 65.5°C but ranged from 65 to 66.4°C. Peak melting temperatures for the test viruses
were inversely proportional to the number of mutations observed between the Del-E mutation probe and target virus
sequence. All the IBDV vaccine strains tested and all but two of the wild-type strains exhibited more than one melting peak,
indicating that genetic subpopulations or quasispecies of the viruses were present in the samples. Since the mutation probe
was located at a site which encodes a neutralizing epitope of the virus, it is possible that the genetic differences observed
are translated into antigenic changes in this VP2 epitope and contribute to antigenic diversity in the quasispecies cloud.INTRODUCTION
Infectious bursal disease virus (IBDV) causes an im-
munosuppressive disease in young chickens. Control of
this disease is through vaccination. Broiler breeder
flocks are vaccinated so that their progeny will be pro-
tected from infection early in life by the resulting mater-
nal immunity. Broilers may or may not be vaccinated
depending on the pathogenicity of wild-type viruses
present in the environment. Two serotypes (1 and 2) of
IBDV are recognized but only serotype 1 viruses have
been shown to cause disease in chickens. Within sero-
type 1 viruses several antigenic subtypes have been
described using both in vitro and in vivo studies (Eterra-
dossi et al., 1997, 1999; Fahey et al., 1991; Ismail and Saif,
1991; Jackwood and Saif, 1987; Oppling et al., 1991;
Rosenberger and Cloud, 1986; Schnitzler et al., 1993;
Snyder et al., 1988; Vakharia et al., 1994). The in vivo
studies generally categorize the antigenic subtypes into
classic or variant strains (Ismail and Saif, 1991; Rosen-
berger and Cloud, 1986). The in vitro studies, conducted
using monoclonal antibodies and nucleotide sequenc-
ing, have categorized serotype 1 subtypes into numerous105antigenically and genetically distinct groups (Eterradossi
et al., 1997, 1999; Fahey et al., 1991; Jackwood and Saif,
1987; Oppling et al., 1991; Schnitzler et al., 1993; Snyder
et al., 1988; Vakharia et al., 1994).
The significance of the in vitro defined antigenic sub-
types with regard to the protection of chickens by vacci-
nation is not fully understood. Although vaccination with
one subtype does not insure protection against a differ-
ent antigenic subtype, studies by Ismail and Saif (1991)
indicated that cross-protection can occur between many
of the IBDV subtypes. They demonstrated that vaccines
prepared from variant viruses will protect birds against a
classic virus designated STC. Cross-protection was also
observed when the viral titers of classic vaccines were
relatively high and a low challenge dose of a variant virus
was used. It was suggested that all subtypes of IBDV
contain shared epitopes that induce cross-protective an-
tibody and that some of these epitopes are not ex-
pressed equally (Ismail and Saif, 1991; Oppling et al.,
1991).
In vivo protection studies and in vitro neutralization
studies suggested that cross-reacting epitopes exist on
antigenic subtypes of IBDV and are responsible for
cross-protection. However, another hypothesis for the in
vivo cross-protection observed between different anti-© 2002 Elsevier Science (USA)
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genic subtypes is that quasispecies expressing different
antigens may exist in the vaccine preparations (Domingo
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et al., 1997). The high mutation frequencies caused by
RNA polymerases permit these viruses to evolve quasi-
species (Holland et al., 1982, 1992). The presence of
these quasispecies in many single-stranded RNA vi-
ruses has been documented (Domingo, 1998; Domingo
et al., 1998; Feigelstock et al., 1996; Holland et al., 1992;
Nix et al., 2000; Ruiz-Jarabo et al., 2000). However, there
is a paucity of evidence for quasispecies in double-
stranded RNA viruses. Bonneau et al. (2001) reported on
the presence of quasispecies in blue-tongue viruses.
Hsu et al. (1995) used RNA fingerprinting to identify
quasispecies in infectious pancreatic necrosis virus, a
Birnavirus related to IBDV. The existence of quasispecies
has not been conclusively demonstrated in IBDV vac-
cines, although some vaccine manufacturers suggest
they are responsible for the cross-protection afforded by
their product.
Hydrophilic peak B in the VP2 protein appears to be
responsible for the formation of one or more neutralizing
epitopes. Frequent mutations in hydrophilic peak B be-
tween amino acids positions 317 and 323 have been
documented by nucleotide sequencing of this region
(Bayliss et al., 1990; Dormitorio et al., 1997; Eterradossi et
al., 1999; Heine et al., 1991; Jackwood et al., 2001b; Lin et
al., 1993; Proffitt et al., 1999; Schnitzler et al., 1993; Va-
kharia et al., 1994). The focus of the current study was on
this hydrophilic peak because of its importance to the
formation of one or more neutralizing epitopes. The re-
sults provide evidence for mutant genomes in the pop-
ulation of viruses present in commercially prepared vac-
cines. Since these mutations are located at a site that
encodes a major neutralizing epitope, they have the
potential to contribute to the antigenic diversity of the
quasispecies.
RESULTS
Information on the genetic variability of double-
stranded RNA viruses is limited. Traditionally, molecular
cloning of viral populations has been used to identify
quasispecies in a sample. This approach, albeit effec-
tive, is time consuming and expensive. Real-time RT/
PCR, followed by melting curve analysis of fluorescence
labeled probes, was chosen because of its potential to
provide genetic variability information on a large number
of samples at a reduced cost of time and labor. Antigenic
variability of IBDV strains continues to make control of
this immunosuppressive disease difficult. Studies on the
genetic variability of many strains of this birnavirus are
needed to ascertain the contribution of quasispecies to
antigenic variability.
Fluorescence began to increase between cycles 30
and 35 during the real-time RT-PCR (Fig. 1). The pres-
ence of a 743-bp RT-PCR product was confirmed in flu-
orescence-positive samples using agarose gel electro-
phoresis (Fig. 2). In all cases, positive LightCycler results
were confirmed by the presence of a DNA band at 743 bp
FIG. 1. Real-time RT-PCR results for IBDV vaccine samples. The Del-E mutation probe labeled with FITC and the anchor probe labeled with
LightCycler Red 640 were used. A fluorescence reading was taken at the end of each annealing step.
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and negative LightCycler samples lacked this band (data
not shown).
Melting curve analysis of the Del-E mutation probe
with its homologous virus indicated that the probe was
dissociating from the Del-E virus template between 65
and 66.4°C with the most common Tm being 65.5°C
(Table 1, Fig. 3). A second melting peak was observed for
the Del-E virus template at approximately 54°C. The two
melting peaks were consistently observed at these tem-
peratures following multiple RT-PCR and melting curve
analysis of the Del-E virus.
Vaccine strains of IBDV had lower melting tempera-
tures compared to the homologous Del-E virus when
tested using the Del-E mutation probe (Table 1). In every
vaccine virus tested, multiple melting peaks were ob-
served. The highest Tm observed for these vaccine
strains was about 10°C below the Tm for Del-E. In the
Bursine, Bursine 2, and Bursine Plus viruses, two melting
peaks were observed (Table 1). The peaks were of sim-
ilar fluorescence intensity but their melting temperatures
were not identical. The Vi BursaG, Vivomune, Univax BD,
S706, Bio Burs 1, and D78 viruses had three melting
peaks at approximately 55, 52, and 44°C (Table 1).
The fluorescence intensity, which is an indicator of the
relative quantities of the viral populations, varied be-
tween peaks for some viruses. In the D78 virus, the peak
at 55°C contained the most fluorescence. The 55 and
52°C peaks of the Vivomune, Univax BD, S706, and Bio
Burs 1 viruses had essentially equal fluorescence but
FIG. 2. Agarose gel electrophoresis of real-time RT-PCR products generated during a LightCycler reaction. Lanes labeled “L” contain 100-bp size
markers. Lanes 1–12 contain the expected 743-bp RT-PCR product for Del-E, SVS 510, Bursine 2, BioBurs W, BioBurs, BioBurs (AB), IBD Blen, Bursine,
BioBurs 1, Bursimune, Bursine Plus, and D78, respectively.
TABLE 1
Melting Curve Data Obtained for IBDV Vaccine Strains Using
a Del-E Mutation Probea
Virus
Tm values (°C)
Peak 1 Peak 2 Peak 3
Del-E 65 54 NAb
Bursine 55 48 NA
Bursine 2 55 47 NA
Bursine Plus 56 48 NA
Vi BursaG 55 52 44
Vivomune 55 52 44
Univax BD 55 52 44
S706 55 52 44
Bio Burs 1 55 52 44
D78 55 52 44
a The melting temperature (Tm) peaks of the Del-E mutation probe are
listed for each vaccine virus.
b NA, not applicable, no melting peak was observed.
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this fluorescence intensity was greater than the fluores-
cence observed in the third peak at 44°C for these
viruses. The Univax BD and Vivomune vaccines, which
are produced by different manufacturers, had identical
overlapping melting peaks with similar fluorescence in-
tensities.
Six pathogenic IBDV strains were tested with the Del-E
mutation probe. The nucleotide sequences of these six
wild-type viruses were previously determined (Jackwood
et al., 2001b) and differences in Tm were observed to be
dependent on the number of mutations between the
Del-E mutation probe and wild-type viruses (Table 2). In
Fig. 4, the Del-E mutation probe was tested against
homologous virus, the U1 wild-type virus (1 mutation),
and the S1 wild-type virus (two mutations). The highest
Tm for Del-E was 65.5°C, while the highest Tm for the U1
and S1 viruses was 63.6 and 62.8°C, respectively (Fig. 4,
Table 2). Two melting peaks were observed for the Del-E,
U1, and S1 viruses in Fig. 4. The second peak observed
for Del-E was at 54°C and corresponded to the results
shown in Fig. 3. The second peaks for U1 and S1 were at
approximately 53.5 and 52°C, respectively. Results of
testing wild-type viruses V1, U1, S1, R1, H2, and T1 with
the Del-E mutation probe are shown in Table 2. The
melting peaks with the highest Tm for each of these
wild-type viruses are listed. Only the V1 virus sequence
matched the Del-E mutation probe sequence exactly.
The highest Tm for this virus was essentially identical to
that observed with the homologous Del-E virus, 65.5°C.
Multiple melting peaks were observed for all the wild-
type viruses except H2 and T1. In general, as the number
of mutations between the Del-E probe and virus template
increased, the Tm of the melting peaks decreased.
FIG. 3. Melting peak analysis of Del-E and the Del-E mutation probe. Vertical lines mark the peak melting temperatures for each virus
subpopulation.
TABLE 2
Nucleotide Sequence at the Hydrophilic Region B Examined Using
the Del-E Mutation Probe
Virus
Nucleotide sequence
at hydrophilic Region Ba Mutationsb
Tm
(°C)c
Del-E 5-GTGATGGTCAGGCAGGGGAACAG-3 0 65.5
V1 5-GTGATGGTCAGGCAGGGGAACAG-3 0 65.5
U1 5-GTGATGGCCAGGCAGGGGAACAG-3 1 63.6
S1 5-GCGATGGTCAGGCAGGGGACCAG-3 2 62.8
R1 5-GCGATGGTCAGGCAGGGGATCAG-3 2 61.4
H2 5-GAGGTGGTCAGGCTGGGGATCAG-3 4 47.8
T1 5-GCAATGGGCAGGCAGAGGATCAG-3 5 43.2
a The mutation probe sequence was designed to be identical to the
Del-E sequence. Nucleotides that differ from the mutation probe se-
quence are underlined and boldface.
b The number of mutations compared to the Del-E mutation probe
sequence.
c The melting temperature (Tm) of the Del-E mutation probe is listed
for each virus.
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DISCUSSION
Real-time RT/PCR was used to identify point mutations
in a nucleotide sequence that encodes a neutralizing
epitope of IBDV. This neutralizing epitope was defined by
the monoclonal antibody 17-82 (Fahey et al., 1991). A
two-probe system was used: a mutation probe that hy-
bridizes to the sequence being examined and an anchor
probe that hybridizes to an adjacent conserved se-
quence. The mutation probe was labeled with FITC and
the anchor probe with LightCycler Red 640. When hybrid-
ized to the RT-PCR product, these two probes are in
close approximation to each other and FRET is observed
(Bernard et al., 2001). In the current study, we used the
dissociation of these probes from the viral RT/PCR prod-
ucts to identify IBDV quasispecies with an identical se-
quence to the mutation probe and quasispecies with one
or more mutations. This procedure is a viable alternative
to cloning and sequencing RT/PCR products which was
used recently to study quasispecies in other viral popu-
lations (Bonneau et al., 2001; Quer et al., 2001; Schneider
and Roossinck, 2001).
The mutation probe sequence was based on se-
quence data from the Del-E IBDV strain. It was designed
to hybridize to the nucleotide sequence that encodes
amino acids 317 to 324. In addition, the Del-E mutation
probe was designed to have an estimated Tm (64.3°C)
lower than the Tm of the anchor probe (68.1°C). This was
done so the mutation probe would always dissociate
before the anchor probe as the temperature increased
during the melting point analysis. Thus, the sequence of
the test virus corresponding to the mutation probe and
not the anchor probe was responsible for the loss of
FRET. Any mutations that occurred in the mutation probe
target sequence were identified by a lower Tm for the
mutation probe. Although it is possible that mutations
could also occur in the anchor probe target sequence
that would lower the Tm of the anchor probe below that
of the mutation probe, this was unlikely because the
anchor probe was designed to hybridize to a relatively
stable sequence of the virus compared to the mutation
probe (Bayliss et al., 1990; Dormitorio et al., 1997; Eter-
radossi et al., 1998; Heine et al., 1991; Jackwood et al.,
2001b; Proffitt et al., 1999; Schnitzler et al., 1993; Vakharia
et al., 1994).
The Del-E mutation probe had a Tm that ranged from
65 to 66.4°C when tested with the homologous Del-E
virus. This was slightly higher than the predicted Tm of
64.3°C and probably due to buffer conditions not ac-
counted for in the Omiga software (Oxford Molecular,
Campbell, CA). The Del-E virus used in these experi-
FIG. 4. Melting peak analysis of Del-E, S1, and U1 viruses. The number of mutations between the Del-E mutation probe and target virus sequence
are designated.
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ments consistently had a second melting peak at approx-
imately 54°C. This peak represents a second population
of viruses that have one or more mutations compared to
the mutation probe sequence (Bernard et al., 2001). All
the vaccine viruses tested had two and in some cases
three melting peaks, indicating they contained a corre-
sponding number of genetically distinct populations at
this site.
The Bursine, Bursine 2, and Bursine Plus viruses each
had two melting peaks; however, the Tm observed for
these peaks differed slightly for each virus, indicating the
quasispecies in these vaccines were not identical. Al-
though they originated from the same field isolate, dif-
ferent hosts were used to generate the Bursine, Bursine
2, and Bursine Plus vaccines. These vaccine viruses
were passed between chicken kidney cell culture, em-
bryonated eggs, and chickens. For example, Bursine
Plus was passed from chickens to chicken kidney cells,
then embryonated eggs, chickens again, and finally em-
bryonated eggs before vaccine preparation. Adaptation
to a new host can represent a bottleneck and repeated
bottlenecks are known to cause a loss in fitness of the
viral population known as Miller’s ratchet (Duarte et al.,
1992; Schneider and Roossinck, 2001). Other vaccine
strains have gone through similar bottlenecks including
plaque purification. The effect of these repeated bottle-
necks on the antigenic diversity within the quasispecies
cloud is not known. This is an important issue because
vaccine manufacturers rely on the diversity of the quasi-
species cloud for immunologic cross-reactions among
IBDV strains. Schneider and Roossinck (2001) reported
that genetic diversity is controlled by host and virus
interactions. They demonstrated that cloud size reached
equilibrium and remained constant in a given host and
that switching hosts affected the cloud structure and size
for a particular virus.
The relative melting peaks heights [d(F 2/F 1)] of the
quasispecies observed in a single vaccine were similar
for some viruses, suggesting the quantities of the sub-
populations were relatively similar in the vaccine prepa-
ration. Other vaccine viruses, such as D78 and Vi Bursa
G, had genetic subpopulations with different melting
peak intensities, suggesting that one or more species
became dominant in the population. Intuitively, the ge-
netic fitness of vaccines may be reduced when one
quasispecies dominates. These vaccine quasispecies
may not be able to successfully compete with wild-type
IBDV strains because of an initial lower fitness of the
genetic population which was described by Quer et al.
(2001) as contingent neutrality.
It is possible that mistakes made in the beginning of
the PCR cycles could amplify to a quantity of RT-PCR
product that was detected by the LightCycler. If one of
these mistakes was in the region of the mutation probe,
it could appear as a subpopulation of virus in the sample.
These mistakes, however, would be random and thus the
melting peak temperatures would be random from one
LightCycler run to the next. The melting peak tempera-
tures for viral subpopulations observed in the current
study were not random. For example, the homologous
population of Del-E virus was observed at approximately
65°C and its subpopulation was always observed at
approximately 54°C (Figs. 3 and 4).
Our results indicated that wild-type IBDV strains also
contained quasispecies at the hydrophilic B region
epitope. The subpopulation that had the highest melting
peak Tm was considered to be the closest sequence
match to the Del-E mutation probe. In the case of the V1
virus, our sequencing studies indicate it should have no
mutations at the Del-E mutation probe site (Jackwood et
al., 2001b). As expected, the Tm of the V1 virus peak
(65°C) matched that observed with the homologous
Del-E virus. Interestingly, the Tm of the V1 quasispecies
cloud also matched the Del-E virus Tm at 54°C. Although
both viruses were isolated from field cases of the dis-
ease, the Del-E virus was from a chicken flock on the
Delmarva peninsula (Rosenberger and Cloud, 1986) and
the V1 virus was from a flock in Georgia (Jackwood and
Sommer, 1998). Both are wild-type pathogenic stains that
did not originate from a common vaccine (Jackwood et
al., 2001a).
Lower Tm peak values were observed for viruses with
multiple mutations at the probe site. The exact Tm ob-
served was dependent on the type of mutation. The Tm
values for a virus population were inversely proportional
to the number of mutations at the mutation probe site but
this relationship was not linear and was dependent on
the base pairs replaced in the mismatch.
Monoclonal antibody studies support the presence of
shared epitopes among IBDV subtypes (Snyder et al.,
1988). These studies also demonstrated that multiple
neutralizing epitopes were present on the VP2 protein of
the virus. Several of these neutralizing monoclonal anti-
bodies have been mapped to specific amino acid se-
quences in the hypervariable region of VP2. Eterradossi
et al. (1998) reported that two monoclonal antibodies
recognized different epitopes in hydrophilic peak B that
are clustered around amino acids 321 and 324, respec-
tively. Heine et al. (1991) reported that neutralizing mono-
clonal antibody 17-82 recognized a conformational-de-
pendent epitope in hydrophilic peak B and that amino
acids 318 (glycine) and 323 (aspartic acid) were critical
for binding. Two other neutralizing monoclonal antibod-
ies 39A and 9-6 were also mapped to the hydrophilic
peak B region of VP2 and these antibodies lost their
ability to bind when amino acid 323 was mutated from
aspartic acid to glutamic acid (Heine et al., 1991). We
chose the sequence of the Del-E mutation probe based
on the amino acids important for the binding of these
neutralizing monoclonal antibodies.
Although the real-time PCR assay described could be
an excellent diagnostic to determine the antigenic rela-
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tionship between a vaccine and wild-type IBDV, not all
nucleotide mutations are translated into amino acid and
thus epitope differences. The U1 virus for example had
one nucleotide mutation compared to the Del-E mutation
probe sequence but no amino acid differences were
observed between this virus and Del-E at this 17-82
defined epitope (Jackwood et al., 2001b). However, as the
number of nucleotide mutations increases, the chance
that one or more will cause an amino acid change also
increases. The T1 virus that was shown to break through
maternal immunity to classic and variant IBDV had five
nucleotide mutations that resulted in three amino acid
changes compared to the 17-82 epitope defined by the
Del-E probe (Jackwood et al., 2001b). These results sug-
gest that low melting peak Tm values such as that ob-
served for T1 could be used to predict which IBDV
strains may have altered the neutralizing epitope defined
by the Del-E mutation probe or any probe selected to a
site known to encode an important viral epitope. This
may not always be the case however. The H2 virus also
had a low melting peak Tm (48°C) and four base muta-
tions that translated into three amino acid mutations
compared to the Del-E virus (Jackwood et al., 2001b).
However, unlike the T1 virus that was shown to break
through maternal immunity to variant and classic IBDV
strains, the maternally immune broilers in that study
were protected from challenge with the H2 virus (Jack-
wood et al., 2001b). Although the three amino acid mu-
tations observed in H2 were different compared to Del-E,
they were similar to amino acids found in quasispecies
from classic viruses (Jackwood et al., 2001b). Maternal
immunity generated by classic virus vaccines probably
protected broilers from the H2 virus challenge in that
study.
We have described the use of real-time RT/PCR to
quickly identify quasispecies at a specific region of the
IBDV viral genome. A limitation to using this technique
to identify quasispecies is that prior sequence knowl-
edge is needed and only small defined regions of the
genome can be examined. Since the entire nucleotide
sequences of many strains of IBDV have been pub-
lished, sequence data may not be limiting for this
virus; however, selecting the region to be examined by
the mutation probe is critical. We elected to examine a
region that encodes a major neutralizing epitope of the
virus defined by monoclonal antibody 17-82. The use
of multiple mutation probes to characterize the IBDV
quasispecies cloud at other genetic sites that affect
antigenicity and virulence may be necessary if this
assay is used as a diagnostic tool. Understanding the
factors that control the IBDV quasispecies cloud may
lead to vaccines that have a better antigenic fitness
and thus afford a broader cross protection for wild-
type strains.
MATERIALS AND METHODS
Viruses
The nucleotide sequence of the Del-E variant strain
(Heine et al., 1991) was used to design the LightCycler
probes and this virus was included in the real-time RT-
PCR analysis. The modified-live vaccine strains of IBDV
tested included BioBurs 1 (Hoechst-Roussel/Tri Bio,
Gainesville, GA), S706 (Merial Select, Inc., Gainesville,
GA), Univax BD (Schering Plough Animal Health, Omaha,
NE), D78 (Intervet, Inc., Millsboro, DE), Bursine Plus (Fort
Dodge Animal Health, Fort Dodge, IA), Bursine 2 (Fort
Dodge Animal Health), Bursine (Fort Dodge Animal
Health), Vivomune (BIOMUNE Co., Lenexa, KS), and
ViBursa G (Vineland Laboratories, Vineland, NJ). Patho-
genic wild-type IBDV strains V1, U1, S1, R1, H2, and T1
were previously described and sequenced in our labo-
ratory (Jackwood et al., 2001b).
Viral RNA extraction
The nucleic acid was extracted directly from virus
particles in the vaccine vials. This was done to eliminate
the possibility of causing genetic mutations in the vi-
ruses that could occur with passage in a host. Vaccine
virus preparations were hydrated in a 5-ml volume of
TNE buffer [10 mM Tris–HCl (pH 8.0), 100 mM NaCl, 1
mM ethylenediaminetetraacetic acid]. Wild-type viruses
and Del-E were propagated in 3-week-old specific-
pathogen-free (SPF) chicks. Bursa from the SPF chicks
were harvested 4 days after inoculation and were ho-
mogenized in TNE buffer. Negative control samples were
prepared from the bursa of noninfected SPF chicks. An
800 l volume of bursa homogenate or vaccine virus
suspension was used to extract the viral RNA as previ-
ously described (Jackwood and Sommer, 1997). The
samples were treated for 1 h at 37°C with 1.0 mg/ml
proteinase K (Sigma Chemical Co., St. Louis, MO) and
0.5% sodium dodecyl sulfate (Sigma Chemical Co.). Fol-
lowing incubation, the samples were extracted with an
equal volume of acid phenol (pH 4.3) (AMRESCO, Solon,
OH) and then with an equal volume of chloro-
form:isoamyl alcohol (24:1). The viral RNA was ethanol
precipitated overnight and then suspended in 100 l of
90% dimethy sulfoxide (DMSO, Sigma Chemical Co.).
Real-time polymerase chain reaction
Real-time RT-PCR was conducted using a LightCycler
instrument (Idaho Technology Inc., Idaho Falls, ID) and
LightCycler-RNA amplification kit for hybridization
probes (Roche, Molecular Biochemicals, Alamedia, CA).
The reactions contained 4 l 5 RT-PCR reaction mix,
4.5 mM MgCl2, 0.25 M of each IBDV primer, 0.2 M of
each probe, 0.5 l viral RNA, and sterile H2O was added
to obtain a final reaction volume of 20 l. Primers used to
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amplify the 743-bp variable sequence region of the VP2
gene were described (Jackwood and Sommer, 1998).
Nucleic acid probes were used in the LightCycler to
detect the presence of amplified product. Sequences of
the probes designed from the Del-E virus sequence were
as follows: Mutation Probe: 5-GTGATGGTCAGGCAGG-
GGAACAG-FITC-3 (Tm  64.3°C); Anchor Probe: 5-
Red 640-TGTCATGGTCGGCAAGTGGGAGCC-3 (Tm 
68.1°C). The two-probe system uses fluorescence res-
onance energy transfer (FRET) (Bernard et al., 2001). The
mutation probe was labeled with fluorescein (FITC) at the
3 end and the anchor probe was labeled with a Red 640
fluorophore at the 5 end (BioChem, Salt Lake City, UT).
The Red 640  fluorescence will only occur when the
probes are in close proximity to each other, hybridized to
the RT-PCR product. The mutation probe was designed
to hybridize to the hydrophilic B region of the VP2 gene
and was labeled at the 3 end. The anchor probe was
located downstream from the mutation probe and was
labeled at the 5 end. One base separated the 3 end of
the mutation probe from the 5 end of the anchor probe.
The melting temperature of the anchor probe was de-
signed to be higher than the mutation probe.
The LightCycler reactions consisted of a reverse tran-
scriptase incubation at 55°C for 7 min, followed by a
denaturation step at 95°C for 5 min and 40 cycles of
denaturation at 95°C for 1 s, annealing at 61°C for 10 s,
and elongation at 72°C for 30 s. A single fluorescence
measure was taken after each annealing step. Following
amplification, a melting curve was determined for the
probes attached to the RT-PCR products. The tempera-
tures examined during the melting analysis were from 35
to 90°C. The entire LightCycler reaction including the
initial reverse transcriptase incubation and melting curve
analysis was 50 min in length.
Data analysis
Fluorescence at 640  was detected by the LightCy-
cler at the end of each annealing step during the PCR
portion of the reaction. The fluorimeter gains were set at
1 (channel 1) and 15 (channel 2). The fluorescence in
channel 1 (F1) was background and channel 2 (F2) con-
tained fluorescence generated by the Red 640 labeled
probe. The fluorescence observed during the PCR cycles
was plotted as F2/F1 versus cycle number. For the melt-
ing peak analysis, the loss of fluorescence, which was
indicative of the mutation probe being denaturated from
the template, was plotted as the first negative derivative
[d(F 2/F 1)] versus temperature change (dT). The result-
ing peak loss of fluorescence corresponds to the Tm for
the mutation probe and the virus RT-PCR product being
analyzed.
The Del-E mutation and anchor probes were designed
with the help of Omiga software (Oxford Molecular,
Campbell, CA). The Tm of these probes was predicted
using this software.
Each RT-PCR reaction in the LightCycler was exam-
ined by agarose gel electrophoresis to confirm the pres-
ence or absence of a 743-bp product. Following the
melting peak analysis, a 1 l volume of each RT-PCR
reaction was placed on 2.5% MetaPhor agarose gels
(FMC Bio-Products, Rockland, ME) and the DNA was
visualized using ethidium bromide staining (Jackwood
and Sommer, 1998).
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